Abstract
Canavan disease (CD) is an autosomal recessive disorder, caused by mutations in the aspartoacylase gene resulting enzyme deficiency. Patients with CD have accumulation of NAAG and NAA in the brain resulting elevated urinary NAAG and NAA. Aspartoacylase gene mutation in the mouse led to multiple genomic abnormalities. Pathophysiological processes implicated in CD include spongy degeneration of the brain possibly by the abnormal genes expression / metabolic levels of NAAG, NAA, aspartate, glutamate, glutamate transporter-EAAT4, GABA receptor-GABRA6 and GABA. In addition, high expression of cell death inducing agents includes serine proteinase inhibitor 2, caspase 11 and interleukin 1- beta. Osteoporosis is also an important consequence in the CD mouse. Each of these pathways offers potential therapeutic targets and pharmacological manipulation.
Keywords: canavan disease, ast, glutamate, eaat4, gabra6, gaba
Current Pharmacogenomics
Title: Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Volume: 2 Issue: 1
Author(s): Sankar Surendran, Stephen K. Tyring, Kimberlee Michals-Matalon and Reuben Matalon
Affiliation:
Keywords: canavan disease, ast, glutamate, eaat4, gabra6, gaba
Abstract: Canavan disease (CD) is an autosomal recessive disorder, caused by mutations in the aspartoacylase gene resulting enzyme deficiency. Patients with CD have accumulation of NAAG and NAA in the brain resulting elevated urinary NAAG and NAA. Aspartoacylase gene mutation in the mouse led to multiple genomic abnormalities. Pathophysiological processes implicated in CD include spongy degeneration of the brain possibly by the abnormal genes expression / metabolic levels of NAAG, NAA, aspartate, glutamate, glutamate transporter-EAAT4, GABA receptor-GABRA6 and GABA. In addition, high expression of cell death inducing agents includes serine proteinase inhibitor 2, caspase 11 and interleukin 1- beta. Osteoporosis is also an important consequence in the CD mouse. Each of these pathways offers potential therapeutic targets and pharmacological manipulation.
Export Options
About this article
Cite this article as:
Surendran Sankar, Tyring K. Stephen, Michals-Matalon Kimberlee and Matalon Reuben, Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease, Current Pharmacogenomics 2004; 2 (1) . https://dx.doi.org/10.2174/1570160043476141
DOI https://dx.doi.org/10.2174/1570160043476141 |
Print ISSN 1570-1603 |
Publisher Name Bentham Science Publisher |
Online ISSN 1570-1603 |
Related Articles
-
Isatin Derivatives and Their Antiviral Properties Against Arboviruses: A Review
Mini-Reviews in Medicinal Chemistry Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Synthesis and Anti-HSV-1 Activity of 1,4-dihydro-4-oxoquinoline Ribonucleosides
Letters in Drug Design & Discovery Editorial [Hot Topic: The Challenge of Viral Encephalitis: From Etiological Diagnosis to Efficient Antiviral Drug Discovery (Guest Editor: Laurent Dacheux)]
Infectious Disorders - Drug Targets Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research The Genetic Basis of Human Cytomegalovirus Resistance and Current Trends in Antiviral Resistance Analysis
Infectious Disorders - Drug Targets Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Mathematical Models for the Management of Helminth Parasites: From Biological Processes to the Evolution of Anthelmintic Resistance
Anti-Infective Agents in Medicinal Chemistry Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques
Infectious Disorders - Drug Targets Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Dengue: Recent Advances in Biology and Current Status of Translational Research
Current Molecular Medicine Synthesis and Biological Evaluation of a Series of 4-(arylamido/imidoalkyl)- 5-(arylideno- 4-oxo-2-thio-imidazolidinyl)-N-(methyl-phenyl-imino) Acridinium Iodides as Potential Antiviral Agents
Letters in Drug Design & Discovery Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins
Current Gene Therapy